Shire plc

(SHPG) Trade

By |

Profile

Shire is a diversified, Ireland-based specialty drug firm. Shire has grown primarily through mergers and acquisitions, including the Transkaryotic Therapies acquisition in 2005, which established its genetic disease business with Replagal and Elaprase, and the merger with New River in 2007, which brought full rights to neuroscience drug Vyvanse. Shire completed the acquisition of ViroPharma (genetic diseases) in 2014, NPS Pharma (internal medicine) in 2015, and Baxalta (hematology, immunology, and oncology) and Dyax (genetic diseases) in 2016.

Contact Information

Website: www.shire.com
Email: investorrelations@shire.com
Main Phone: +353 16096000
Address: 50-58 Baggot Street Lower
Address 2: Block 2, Miesian Plaza
City / Town: Dublin
Country: IRL
Postal Code: 2

Issuer Information

Exchange: NGS
CEO: Flemming Ornskov
Employees: 23044
NAICS: Pharmaceutical Preparation Manufacturing(325412)
$ 172.48 $ 2.82 (1.66%)
Last Price 172.48 Change $ 2.82 Change % 1.66 Tick N/A
Bid 176.26 Bid Size 600.00 Ask 176.43 Ask Size 100.00
Open 171.85 High 173.12 Low 171.60 Prev Close 169.66
Last Trade Volume 2 mi 52 Wk Hi 182.47 52 Wk Low 123.73
Market Cap 52.7 bi Ex-Div Date Div Rate 0.34 Yield 0.1950
Shares 305,296,041.00 EPS (TTM) 15.75 PE Ratio 10.80 Exchange NGS
  Current 1 Week Ago 2 Weeks Ago 3 Weeks Ago
High Target Price Estimate 238 238 238 238
Low Target Price Estimate 164 164 164 164
Mean Target Price Estimate 207 207 207 207
Standard Deviation 24.9 24.9 24.9 24.9
Date of Most Recent Estimate 05/10/18 05/10/18 05/10/18 05/10/18
  Current 1 Month Ago 2 Months Ago 3 Months Ago
Strong Buy 10 10 10 10
Moderate Buy 1 1 1 1
Hold 2 2 2 3
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.38 1.38 1.38 1.5